Effects of acute inhalation of the bronchodilator, albuterol, on power output

Joseph Signorile, T. A. Kaplan, B. Applegate, Arlette Perry

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

This study was designed to examine the effects of acute inhalation of the bronchodilator, albuterol (Proventil, Schering Corp.), on high intensity power output. Fifteen healthy nonasthmatic subjects (eight male, seven female, 18-33 yr) performed four supramaximal 15-s rides on a bicycle ergometer. Rides were arranged in pairs with a 10-min rest interval. Each pair of rides was preceded by a 5-min warm-up. Sessions were separated by a minimum of 48 h. The study design was fully randomized and double blind. Ten minutes prior to each pair of rides subjects inhaled two metered doses (180 μg) of albuterol (A) or a placebo (P). Individual ANOVAs revealed a significant difference between the A and P treatment for peak power (A = 886.6 W, P = 858.3 W) and fatigue (A = 27.2%, P = 24.4%). Mean changes in FEF25-75% (A = 0.712, P = 0.040 1 · s-1), FEV1.0 (A = 0.188, P = 0.007 1), and PEF (A = 0.573, P = -0.1551 · s-1) were also statistically significant; however, these changes did not correlate to the anaerobic performance changes. No significant differences were found between treatments for heart rate increases resulting from the power test (A = 56.73 bpm, P = 53.20 bpm). These results indicate an ergogenic effect of the bronchodilator on short-term power output independent of impact on respiratory smooth muscle, with no effect on cardiac response.

Original languageEnglish
Pages (from-to)638-642
Number of pages5
JournalMedicine and Science in Sports and Exercise
Volume24
Issue number6
StatePublished - Jan 1 1992

Fingerprint

Albuterol
Bronchodilator Agents
Inhalation
Performance-Enhancing Substances
Respiratory Muscles
Fatigue
Smooth Muscle
Analysis of Variance
Healthy Volunteers
Heart Rate
Placebos
Therapeutics

Keywords

  • β AGONIST
  • PEAK POWER OUTPUT
  • SHORT-TERM FATIGUE

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Public Health, Environmental and Occupational Health
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Effects of acute inhalation of the bronchodilator, albuterol, on power output. / Signorile, Joseph; Kaplan, T. A.; Applegate, B.; Perry, Arlette.

In: Medicine and Science in Sports and Exercise, Vol. 24, No. 6, 01.01.1992, p. 638-642.

Research output: Contribution to journalArticle

@article{1f08fe14d4b74d52b8aa7124f0ba49be,
title = "Effects of acute inhalation of the bronchodilator, albuterol, on power output",
abstract = "This study was designed to examine the effects of acute inhalation of the bronchodilator, albuterol (Proventil, Schering Corp.), on high intensity power output. Fifteen healthy nonasthmatic subjects (eight male, seven female, 18-33 yr) performed four supramaximal 15-s rides on a bicycle ergometer. Rides were arranged in pairs with a 10-min rest interval. Each pair of rides was preceded by a 5-min warm-up. Sessions were separated by a minimum of 48 h. The study design was fully randomized and double blind. Ten minutes prior to each pair of rides subjects inhaled two metered doses (180 μg) of albuterol (A) or a placebo (P). Individual ANOVAs revealed a significant difference between the A and P treatment for peak power (A = 886.6 W, P = 858.3 W) and fatigue (A = 27.2{\%}, P = 24.4{\%}). Mean changes in FEF25-75{\%} (A = 0.712, P = 0.040 1 · s-1), FEV1.0 (A = 0.188, P = 0.007 1), and PEF (A = 0.573, P = -0.1551 · s-1) were also statistically significant; however, these changes did not correlate to the anaerobic performance changes. No significant differences were found between treatments for heart rate increases resulting from the power test (A = 56.73 bpm, P = 53.20 bpm). These results indicate an ergogenic effect of the bronchodilator on short-term power output independent of impact on respiratory smooth muscle, with no effect on cardiac response.",
keywords = "β AGONIST, PEAK POWER OUTPUT, SHORT-TERM FATIGUE",
author = "Joseph Signorile and Kaplan, {T. A.} and B. Applegate and Arlette Perry",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "24",
pages = "638--642",
journal = "Medicine and Science in Sports and Exercise",
issn = "0195-9131",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Effects of acute inhalation of the bronchodilator, albuterol, on power output

AU - Signorile, Joseph

AU - Kaplan, T. A.

AU - Applegate, B.

AU - Perry, Arlette

PY - 1992/1/1

Y1 - 1992/1/1

N2 - This study was designed to examine the effects of acute inhalation of the bronchodilator, albuterol (Proventil, Schering Corp.), on high intensity power output. Fifteen healthy nonasthmatic subjects (eight male, seven female, 18-33 yr) performed four supramaximal 15-s rides on a bicycle ergometer. Rides were arranged in pairs with a 10-min rest interval. Each pair of rides was preceded by a 5-min warm-up. Sessions were separated by a minimum of 48 h. The study design was fully randomized and double blind. Ten minutes prior to each pair of rides subjects inhaled two metered doses (180 μg) of albuterol (A) or a placebo (P). Individual ANOVAs revealed a significant difference between the A and P treatment for peak power (A = 886.6 W, P = 858.3 W) and fatigue (A = 27.2%, P = 24.4%). Mean changes in FEF25-75% (A = 0.712, P = 0.040 1 · s-1), FEV1.0 (A = 0.188, P = 0.007 1), and PEF (A = 0.573, P = -0.1551 · s-1) were also statistically significant; however, these changes did not correlate to the anaerobic performance changes. No significant differences were found between treatments for heart rate increases resulting from the power test (A = 56.73 bpm, P = 53.20 bpm). These results indicate an ergogenic effect of the bronchodilator on short-term power output independent of impact on respiratory smooth muscle, with no effect on cardiac response.

AB - This study was designed to examine the effects of acute inhalation of the bronchodilator, albuterol (Proventil, Schering Corp.), on high intensity power output. Fifteen healthy nonasthmatic subjects (eight male, seven female, 18-33 yr) performed four supramaximal 15-s rides on a bicycle ergometer. Rides were arranged in pairs with a 10-min rest interval. Each pair of rides was preceded by a 5-min warm-up. Sessions were separated by a minimum of 48 h. The study design was fully randomized and double blind. Ten minutes prior to each pair of rides subjects inhaled two metered doses (180 μg) of albuterol (A) or a placebo (P). Individual ANOVAs revealed a significant difference between the A and P treatment for peak power (A = 886.6 W, P = 858.3 W) and fatigue (A = 27.2%, P = 24.4%). Mean changes in FEF25-75% (A = 0.712, P = 0.040 1 · s-1), FEV1.0 (A = 0.188, P = 0.007 1), and PEF (A = 0.573, P = -0.1551 · s-1) were also statistically significant; however, these changes did not correlate to the anaerobic performance changes. No significant differences were found between treatments for heart rate increases resulting from the power test (A = 56.73 bpm, P = 53.20 bpm). These results indicate an ergogenic effect of the bronchodilator on short-term power output independent of impact on respiratory smooth muscle, with no effect on cardiac response.

KW - β AGONIST

KW - PEAK POWER OUTPUT

KW - SHORT-TERM FATIGUE

UR - http://www.scopus.com/inward/record.url?scp=0026648145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026648145&partnerID=8YFLogxK

M3 - Article

C2 - 1318486

AN - SCOPUS:0026648145

VL - 24

SP - 638

EP - 642

JO - Medicine and Science in Sports and Exercise

JF - Medicine and Science in Sports and Exercise

SN - 0195-9131

IS - 6

ER -